3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Breast Neoplasms
59
Neoplasm Metastasis
24
Stomach Neoplasms
12
Carcinoma, Non-Small-Cell Lung
11
Colorectal Neoplasms
10
Neoplasms
8
Brain Neoplasms
7
Triple Negative Breast Neoplasms
5
Adenocarcinoma
5
Recurrence
3
Pancreatic Neoplasms
3
Ovarian Neoplasms
3
Esophageal Neoplasms
3
Endometrial Neoplasms
3
Advanced Solid Tumor
3
Salivary Gland Neoplasms
2
Meningeal Carcinomatosis
2
HER2-positive Breast Cancer
2
Colonic Neoplasms
2
Breast Cancer With Brain Metastasis
2
Advanced Breast Cancer
2
Adenocarcinoma Of Esophagus
2
Uterine Neoplasms
1
Unresectable Locally Recurrent Breast Cancer
1
Solid Cancer
1
Sarcoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Osteosarcoma
1
Interventions
Temozolomide
111
Radiotherapy
60
Carboplatin
30
Bevacizumab
30
Magnetic Resonance Spectroscopy
28
Carmustine
28
Filgrastim
23
Surgical Procedures, Operative
22
Irinotecan
22
Radiation
17
Lomustine
16
Vincristine
15
Etoposide
15
Specimen Handling
13
Peripheral Blood Stem Cell Transplantation
13
O(6)-benzylguanine
13
Radiotherapy, Intensity-Modulated
12
Procarbazine
11
Erlotinib Hydrochloride
11
Cyclophosphamide
11
Chemotherapy, Adjuvant
11
sargramostim
10
Thiotepa
10
Cisplatin
10
Flucytosine
9
Everolimus
9
antineoplaston AS 2-1
8
antineoplaston A10
8
Granulocyte Colony-Stimulating Factor
8
Vorinostat
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Astrocytoma
×
trastuzumab deruxtecan
×
Clear all
NCT05417594
2026-06-02
CERTIS1
AstraZeneca
Phase 1/2
Recruiting
695 enrolled